Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer

Publisher： Karger

E-ISSN： 1421-9794|60|2|91-98

ISSN： 0009-3157

Source： Chemotherapy, Vol.60, Iss.2, 2015-02, pp. : 91-98

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Retrospective Study of Gemcitabine and Cisplatin Combination Therapy as Second-Line Treatment for Advanced Biliary Tract Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-09 ,pp. : 106-111

Karger

Access to resources Recommend Favorite

Prospective Phase II Trial of Gemcitabine in Combination with Irinotecan as First-Line Chemotherapy in Patients with Advanced Biliary Tract Cancer

By  

Chemotherapy, Vol. 57, Iss. 3, 2011-05 ,pp. : 236-243

Karger

Access to resources Recommend Favorite

Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

By  

Chemotherapy, Vol. 57, Iss. 1, 2011-02 ,pp. : 71-76

Karger

Access to resources Recommend Favorite

Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study

By  

Chemotherapy, Vol. 58, Iss. 3, 2012-07 ,pp. : 225-232

Karger

Access to resources Recommend Favorite

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy

By  

Chemotherapy, Vol. 59, Iss. 4, 2014-01 ,pp. : 273-279

Karger

Access to resources Recommend Favorite